---
title: 'Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients:
  mutation frequencies, testing intention, and clinical impact'
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39839709/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250122171154&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Circulating cell-free tumor DNA (ctDNA) provides a non-invasive
  approach for assessing somatic alterations. The German PRAEGNANT registry study
  aims to explore molecular biomarkers and investigate their integration into clinical
  practice. In this context, ctDNA testing was included to understand the motivations
  of clinicians to initiate testing, to identify somatic alterations, and to assess
  the clinical impact of the results ...'
disable_comments: true
---
BACKGROUND: Circulating cell-free tumor DNA (ctDNA) provides a non-invasive approach for assessing somatic alterations. The German PRAEGNANT registry study aims to explore molecular biomarkers and investigate their integration into clinical practice. In this context, ctDNA testing was included to understand the motivations of clinicians to initiate testing, to identify somatic alterations, and to assess the clinical impact of the results ...